Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 9/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.30 |
| ▸ | FNTA | P49354 | 4/20 | 0.30 |
| ▸ | FNTB | P49356 | 4/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26241037 | 0.89 | FURIN (0.37) | FURINPRSS1SIRT5 | |
| SCHEMBL23969120 | 0.86 | FURIN (0.33) | FURINSIRT5 | |
| SCHEMBL24714725 | 0.86 | FURIN (0.33) | FURINSIRT5 | |
| SCHEMBL21262052 | 0.82 | C3AR1 (0.34) | — | |
| SCHEMBL18556660 | 0.81 | FURIN (0.35) | FURINSIRT5FNTAFNTB | |
| SCHEMBL21788004 | 0.81 | FURIN (0.36) | FURINPRSS1BACE1SIRT5 | |
| SCHEMBL19703924 | 0.81 | FURIN (0.34) | FURIN | |
| SCHEMBL22853960 | 0.80 | FURIN (0.37) | FURINPRSS1SIRT5 | |
| SCHEMBL24173258 | 0.79 | C3AR1 (0.34) | FURINSIRT5 | |
| SCHEMBL21914949 | 0.79 | C3AR1 (0.34) | FURINSIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200405813-A1 | IMMUNOMODULATOR ANTIBODY DRUG CONJUGATES AND USES THEREOF | SUTRO BIOPHARMA, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200405813-A1 | IMMUNOMODULATOR ANTIBODY DRUG CONJUGATES AND USES THEREOF | FCGR2A, FCGR1A, FCGR3B | FURIN 3545/4885PRSS1 4822/4885BACE1 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.